公开(公告)号：US20210024553A1

公开(公告)日：2021-01-28

申请号：US16989235

申请日：2020-08-10

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Helene G. BAZIN-LEE ,  Laura S. BESS ,  David A. JOHNSON

IPC: C07F9/6558 ,  C07F9/10 ,  C07F9/6561

Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.

公开(公告)号：US20180273560A1

公开(公告)日：2018-09-27

申请号：US16060142

申请日：2016-12-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Helene G. BAZIN-LEE ,  Laura S. BESS ,  David A. JOHNSON

IPC: C07F9/6558 ,  C07F9/6561 ,  C07F9/10

Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.

公开(公告)号：US20220119428A1

公开(公告)日：2022-04-21

申请号：US17566247

申请日：2021-12-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Helene G. BAZIN-LEE ,  Laura S. BESS ,  David A. JOHNSON

IPC: C07F9/6558 ,  C07F9/10 ,  C07F9/6561

Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor (TLR8)—active imidazoquinolines and oxoadenines.